Coherus BioSciences Analyst Ratings
Buy Rating Affirmed for Coherus Biosciences on CHS-114's Promising Clinical Data and Strong Financial Projections
Coherus BioSciences Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)
Coherus Biosciences (CHRS) Gets a Hold From Maxim Group
Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)
Coherus BioSciences Analyst Ratings
Buy Rating Affirmed for Coherus Biosciences Amid Strong Udenyca Sales and Strategic Financial Management
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
Coherus BioSciences Analyst Ratings
Buy Rating on Coherus Biosciences: Balancing Divestiture With Promising Pipeline and Financial Growth
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)
Coherus BioSciences Analyst Ratings
Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring
Barclays Sticks to Their Buy Rating for Coherus Biosciences (CHRS)
Coherus BioSciences Analyst Ratings
Coherus BioSciences Analyst Ratings
Barclays Gives a Buy Rating to Coherus Biosciences (CHRS)
No Data